All Stories

  1. Clinical profiles and prognosis of acute heart failure in adult patients with dystrophinopathies on home mechanical ventilation
  2. Swallowing and swallowing-breathing interaction as predictors of intubation in Guillain-Barré syndrome
  3. Cardiac implantable electronic devices in tracheotomized muscular dystrophy patients: Safety and risks
  4. Prognostic Value of Initial Assessment of Residual Hypoventilation Using Nocturnal Capnography in Mechanically Ventilated Neuromuscular Patients: A 5-Year Follow-up Study
  5. Pharmacokinetics of oral fludrocortisone in septic shock
  6. Erratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
  7. Comparison of ventilator-integrated end-tidal CO2 and transcutaneous CO2 monitoring in home-ventilated neuromuscular patients
  8. Heart rate reduction may be a major determinant of vascular tone in esmolol-treated septic shock patients—although still remains to be confirmed!
  9. Beta-blockers in septic shock to optimize hemodynamics? We are not sure
  10. The Role of ACTH and Corticosteroids for Sepsis and Septic Shock: An Update
  11. Prognostic value of SSEP and BAEP in a cohort of deeply sedated mechanically ventilated critically ill patients
  12. Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial
  13. Natural History of Cardiac and Respiratory Involvement, Prognosis and Predictive Factors for Long-Term Survival in Adult Patients with Limb Girdle Muscular Dystrophies Type 2C and 2D
  14. Management of carbon monoxide poisoning
  15. Inotropic agents in critical illness
  16. Adjunctive treatment in septic shock: What's next?
  17. Is the literature inconclusive about the harm from HES? Yes
  18. Light therapy and chronobiology in critical illness
  19. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
  20. Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: yes
  21. Fatal tramadol-induced multiple organ failure
  22. Criteria for initiation of invasive ventilation in septic shock: An international survey
  23. What Is the Evidence for Harm of Neuromuscular Blockade and Corticosteroid Use in the Intensive Care Unit?
  24. Emerging drugs for the treatment of sepsis
  25. Corticosteroids for treating sepsis
  26. Judging quality of current septic shock definitions and criteria
  27. Early Standard Electroencephalogram Abnormalities Predict Mortality in Septic Intensive Care Unit Patients
  28. Evidence to Practice Gap
  29. Nocturnal hypoventilation in neuromuscular disease: prevalence according to different definitions issued from the literature
  30. Prognostic value of residual hypoventilation in mechanically ventilated neuromuscular patients: A 5 years follow-up study
  31. Neuropathological Correlates of Hyperglycemia During Prolonged Polymicrobial Sepsis in Mice
  32. Early goal-directed therapy: from discovery through enthusiasm to equipoise?
  33. Corticosteroids and pneumonia: time to change practice
  34. Erratum to: Outcome of acute mesenteric ischemia in the intensive care unit: a retrospective, multicenter study of 780 cases
  35. Critical Care Evidence—New Directions
  36. Outcome of acute mesenteric ischemia in the intensive care unit: a retrospective, multicenter study of 780 cases
  37. Cognitive decline after sepsis
  38. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders
  39. Critical illness-induced dysglycemia and the brain
  40. Year in review 2013: Critical Care – sepsis
  41. Fluid Resuscitation in Sepsis
  42. Erratum to: Clinical practice guideline on diagnosis and treatment of hyponatraemia
  43. Paving a New Road for Generating Evidence-Based Care in Sepsis*
  44. Plasma l-citrulline concentrations and its relationship with inflammation at the onset of septic shock: A pilot study
  45. Diastolic function in Steinert’s disease
  46. Erratum to: Clinical practice guideline on diagnosis and treatment of hyponatraemia
  47. Mortality in Patients With Hypovolemic Shock Treated With Colloids or Crystalloids—Reply
  48. Successful cardiac resynchronisation therapy in Duchenne muscular dystrophy: A 5-year follow-up
  49. Clinical practice guideline on diagnosis and treatment of hyponatraemia
  50. Left ventricular function in alpha-sarcoglycanopathy and gamma-sarcoglycanopathy
  51. Right ventricular function in late-onset Pompe disease
  52. Mitochondrial Diseases
  53. Experimental and clinical evidences for glucose control in intensive care: is infused glucose the key point for study interpretation?
  54. Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia
  55. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial
  56. The authors reply
  57. The authors reply
  58. The authors reply
  59. Predictive power of heart rate complexity to estimate severity in severe sepsis patients
  60. Effects of Fluid Resuscitation With Colloids vs Crystalloids on Mortality in Critically Ill Patients Presenting With Hypovolemic Shock
  61. Thirst Perception and Osmoregulation of Vasopressin Secretion Are Altered During Recovery From Septic Shock
  62. The authors reply
  63. The authors reply
  64. Wolff–Parkinson–White syndrome in Duchenne muscular dystrophy
  65. Right ventricular function in Steinert's disease
  66. Recombinant Human Activated Protein C for Adults with Septic Shock. A Randomized Controlled Trial
  67. Human plasma quantification of fludrocortisone using liquid chromatography coupled with atmospheric pressure chemical ionization mass spectrometry after low-dosage administration
  68. Cardiac asynchrony in Duchenne muscular dystrophy
  69. Acute ischemic stroke in gamma-sarcoglycanopathy
  70. Dynamic Data During Hypotensive Episode Improves Mortality Predictions Among Patients With Sepsis and Hypotension*
  71. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease
  72. StO2 guided early resuscitation in subjects with severe sepsis or septic shock: a pilot randomised trial
  73. Is Prolonged Low-Dose Glucocorticoid Treatment Beneficial in Community-Acquired Pneumonia?
  74. Surviving Sepsis Campaign
  75. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
  76. Pattern of Brain Injury in the Acute Setting of Human Septic Shock
  77. Understanding brain dysfunction in sepsis
  78. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial
  79. Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study
  80. 644
  81. Plagiats dans les facultés de médecine, et leur prévention
  82. Early-Onset Ventilator-Associated Pneumonia in Adults Randomized Clinical Trial: Comparison of 8 versus 15 Days of Antibiotic Treatment
  83. Plasma exchange for Guillain-Barré syndrome
  84. Choc septique, des recherches à poursuivre
  85. Les enjeux du traitement du choc septique
  86. Impact of Hyperglycemia on Neuropathological Alterations during Critical Illness
  87. Supine volume drop and diaphragmatic function in adults with Pompe disease: Table 1–
  88. Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock
  89. The Absence of Adrenal Gland Enlargement During Septic Shock Predicts Mortality
  90. Physicians no longer should consider dopamine for septic shock!*
  91. Masseter tissue oxygen saturation predicts normal central venous oxygen saturation during early goal-directed therapy and predicts mortality in patients with severe sepsis*
  92. A1M
  93. AAA
  94. AAST Spleen Injury Scale
  95. Abbreviated Injury Scale
  96. Abbreviated Laparotomy
  97. ABCDEs
  98. Abdominal Aortic Aneurysm
  99. Abdominal Aortic Aneurysm: Diagnosis and Management
  100. Vasopressin and terlipressin in adult vasodilatory shock
  101. Relevance of anxiety in clinical practice of Guillain-Barré syndrome: a cohort study
  102. Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)
  103. Abdominal Cavity Infections
  104. Abdominal Compartment Syndrome
  105. Abdominal Pain
  106. Abdominal Pressure
  107. Abdominal Sepsis
  108. Abdominal Trauma
  109. Abdominal Trauma, Damage Control
  110. ABG
  111. Abscess
  112. Abscess, Epidural
  113. Accelerated Recovery
  114. Accessory Splenic Tissue
  115. Acetaminophen Overdose
  116. Acetylsalicylic Acid Overdose
  117. Ache
  118. Acid Fast Bacilli (AFB)
  119. Acid–Base
  120. Acid–Base Assessment
  121. Acid–Base Evaluation
  122. Acinetobacter Bacteremia
  123. Acinetobacter Central Venous Catheter Infection
  124. Acinetobacter Cholangitis
  125. Acinetobacter ICU-Acquired Infection
  126. Acinetobacter Infections
  127. Acinetobacter Meningitis
  128. Acinetobacter Peritonitis
  129. Acinetobacter Skin Infection
  130. Acinetobacter Urine Tract Infection
  131. Acinetobacter Urosepsis
  132. Acinetobacter Ventilator-Associated Pneumonia
  133. Acinetobacter Wound Infection
  134. Acquired Aneurysm
  135. Acquired Immunodeficiency Syndrome
  136. ACT Analyzer
  137. Active Surveillance Cultures
  138. Acute Abdomen
  139. Acute Abdominal Pain: General Approach
  140. Acute Acalculous Cholecystitis
  141. Acute Asthma
  142. Acute Bacterial Prostatitis
  143. Acute Brain Dysfunction
  144. Acute Brain Failure
  145. Acute Calculous Cholecystitis
  146. Acute Cardiogenic Pulmonary Edema (ACPE)
  147. Acute Care Surgery
  148. Acute Cholecystitis
  149. Acute Coagulopathy of Trauma
  150. Acute Confusional State
  151. Acute Coronary Syndrome: Risk Stratification
  152. Acute Heart Failure
  153. Acute Heart Failure: Risk Stratification
  154. Acute Intracerebral Hemorrhage
  155. Acute Iron Poisoning
  156. Acute Ischemic Stroke
  157. Acute Kidney Disease
  158. Acute Kidney Diseases and Disorders (AKD)
  159. Acute Kidney Dysfunction
  160. Acute Kidney Failure
  161. Acute Kidney Injury (AKI)
  162. Acute Kidney Injury Biomarkers, Concept of
  163. Acute Kidney Injury During Pregnancy
  164. Acute Kidney Insufficiency
  165. Acute Myocardial Dysfunction
  166. Acute Myocardial Infarction (MI)
  167. Acute Myocardial Inflammation
  168. Acute Pancreatitis
  169. Acute Phase Proteins
  170. Acute Pulmonary Edema
  171. Pathophysiology of acute respiratory distress syndrome. Glucocorticoid receptor-mediated regulation of inflammation and response to prolonged glucocorticoid treatment
  172. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis
  173. Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic
  174. Effect of a tracheostomy speaking valve on breathing–swallowing interaction
  175. Changes in CRH and ACTH Synthesis during Experimental and Human Septic Shock
  176. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns
  177. R2: The Absence of Adrenal Gland Enlargement during Septic Shock Predicts Mortality
  178. Brainstem responses can predict death and delirium in sedated patients in intensive care unit*
  179. Thenar tissue oxygen saturation monitoring: Noninvasive does not mean simple or accurate!*
  180. Glucocorticoid Treatment in Acute Lung Injury and Acute Respiratory Distress Syndrome
  181. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease
  182. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock
  183. Pro: the Illegitimate Crusade against Corticosteroids for Severe H1N1 Pneumonia
  184. The Absence Of Adrenal Gland Enlargement During Septic Shock Predicts Mortality: A CT-Scan Study Of 239 Patients
  185. A lethal case of meningitis due to Lactobacillus rhamnosus as a late complication of anterior cervical spine surgery
  186. Adrenocortical cell tolerance to lipopolysaccharide: A new mechanism for Critical Illness Related Corticosteroid Insufficiency*
  187. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials: reply to comment by Birmingham and Hoffman
  188. Critical Care Handbook of the Massachusetts General Hospital
  189. Year in review 2010: Critical Care - multiple organ dysfunction and sepsis
  190. Robust Virtual Keyboard for Brain-Computer Interface (ROBIK): An Halfway Update on the Project
  191. Evidence-based support for prolonged glucocorticoid treatment in acute lung injury/acute respiratory distress syndrome
  192. Corticosteroids for severe sepsis: an evidence-based guide for physicians
  193. Glucocorticoids in sepsis: dissecting facts from fiction
  194. Hyperglycaemia and apoptosis of microglial cells in human septic shock
  195. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials
  196. Sepsis-associated encephalopathy and its differential diagnosis
  197. Osmoregulation of vasopressin secretion is altered in the postacute phase of septic shock*
  198. Health-Related Quality of Life in Family Members of Intensive Care Unit Patients
  199. Impact of tracheostomy on swallowing performance in Duchenne muscular dystrophy
  200. Treatment of Osteoradionecrosis of the Jaw: The Case Against the Use of Hyperbaric Oxygen
  201. Human and experimental septic shock are characterized by depletion of lipid droplets in the adrenals
  202. Masseter muscle oxygen saturation is associated with central venous oxygen saturation in patients with severe sepsis
  203. Adjunct Therapy for Sepsis: How Early?
  204. Tight Glycemic Control in Critically Ill Patients—Reply
  205. Vasopressin Synthesis by the Magnocellular Neurons is Different in the Supraoptic Nucleus and in the Paraventricular Nucleus in Human and Experimental Septic Shock
  206. Clinical research ethics for critically ill patients: A pandemic proposal
  207. Prolonged glucocorticoid treatment and secondary prevention in acute respiratory distress syndrome
  208. Long-term outcome of iatrogenic gas embolism
  209. Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders
  210. Defining critical illness-related corticosteroid insufficiency: One step forward!*
  211. Percutaneous Extracorporeal Membrane Oxygenation for Cardiogenic Shock Due to Acute Fulminant Myocarditis
  212. Maladie mitochondriale
  213. Nocturnal Noninvasive Mechanical Ventilation
  214. Corticosteroids for sepsis: registry versus Cochrane systematic review!
  215. Is There a Mineralocorticoid Deficiency in Critically Ill Patients? How Can It Be Diagnosed? Should It Be Treated?
  216. A balanced view of balanced solutions
  217. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease
  218. Thirty years of critical care medicine
  219. Refeeding syndrome influences outcome of anorexia nervosa patients in intensive care unit: an observational study
  220. Mechanisms of Brain Signaling During Sepsis
  221. Activation and Regulation of Systemic Inflammation in ARDS
  222. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics
  223. Pacemaker Implantation for Sinus Node Dysfunction in a Young Patient With Duchenne Muscular Dystrophy
  224. Corticosteroid Therapy for Severe Sepsis and Septic Shock—Reply
  225. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease
  226. Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock
  227. Étude de la toxicocinétique de l’hexobarbital après intoxication aiguë polymédicamenteuse
  228. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock
  229. Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: A multicenter, prospective, randomized, double-blind, placebo-controlled, 4-week trial
  230. Plasma cortisol levels in Guillain-Barré syndrome
  231. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study
  232. Steroids in Patients With Septic Shock
  233. Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults
  234. Sepsis-Associated Delirium
  235. Prolonged glucocorticoid treatment in acute respiratory distress syndrome: Evidence supporting effectiveness and safety*
  236. Vasopressin plus corticosteroids: The shock duo!*
  237. Adrenal Insufficiency in Septic Shock
  238. Automatic air-leak compensation in neuromuscular patients: A feasibility study
  239. Hippocampus: a future target for sepsis treatment!
  240. Improving clinical trials in the critically ill: Unique challenge—Sepsis
  241. Sepsis-associated delirium: the pro and con of C5a blockade
  242. Bench-to-bedside review: β-Adrenergic modulation in sepsis
  243. Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia
  244. Guillain‐Barré Syndrome and Influenza Virus Infection
  245. The Neuroendocrine Response to Sepsis
  246. Corticoïdes
  247. The authors reply
  248. Quel est le devenir des patients ayant souffert de syndrome de détresse respiratoire aigu de l’adulte ?
  249. Corticosteroids and Human Recombinant Activated Protein C for Septic Shock
  250. Place de l’aspirine dans le traitement médicamenteux de l’accident de désaturation
  251. The Hypothalamic Pituitary Adrenal Axis in Sepsis
  252. New recommendations for the use of corticosteroids in sepsis: Not so fast!
  253. Adrenal Insufficiency in Sepsis
  254. Incidence and Prognosis of Sustained Arrhythmias in Critically Ill Patients
  255. Endocrine effects of vasopressin in critically ill patients
  256. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine
  257. Hydrocortisone effects on cardiovascular variability in septic shock: A spectral analysis approach*
  258. Atteintes cardiaques au cours de la myopathie de Duchenne
  259. Bedside adherence to clinical practice guidelines in the intensive care unit: the TECLA study
  260. Hydrocortisone Therapy for Patients with Septic Shock
  261. The Adrenal Response to Critical Illness
  262. Pompe Disease in Adults-Advanced Stage
  263. Pompe Disease: Pulmonology Perspectives
  264. The Encephalopathy in Sepsis
  265. Corticosteroids for community-acquired pneumonia: time to act!
  266. Adrenal glands/corticosteroids and multiple organ dysfunction syndrome
  267. The endocrine cutting edge of critical illness
  268. Prohormones: novel biomarkers for corticosteroids in septic shock?
  269. Corticosteroids for sepsis: Controversial forever?
  270. Use of pressors in the management of septic shock – Authors' reply
  271. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature
  272. Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model
  273. The Diagnosis of Relative Adrenal Insufficiency: The Long and Winding Road…
  274. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders
  275. Metabolism modulators in sepsis: The abnormal pituitary response
  276. Corticosteroids in ARDS
  277. Acute lung injury and acute respiratory distress syndrome
  278. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial
  279. Enlarged adrenals during septic shock
  280. On the Diagnosis of Adrenal Insufficiency in Severe Sepsis and Septic Shock
  281. Sepsis-associated delirium
  282. Glucocorticoids for ARDS
  283. No Blood Testing in Relative Adrenal Insufficiency: Just Treat!
  284. Adrenal function in sepsis: The retrospective Corticus cohort study
  285. Brain lesions in septic shock: a magnetic resonance imaging study
  286. Does intensive insulin therapy affect the cortisol response of critically ill patients?
  287. Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study
  288. Cost-effectiveness of activated protein C in real-life clinical practice
  289. Diagnosis of Adrenal Insufficiency in Severe Sepsis and Septic Shock
  290. GLOBAL UTILIZATION OF LOW DOSE CORTICOSTEROIDS IN SEVERE SEPSIS: A REPORT FROM THE PROGRESS REGISTRY.
  291. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study
  292. Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain–Barré syndrome
  293. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy
  294. Dissociation of Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate in Septic Shock
  295. Exploring the Role of Etomidate in Septic Shock and Acute Respiratory Distress Syndrome
  296. Compartmentalization of the inflammatory response in sepsis and SIRS
  297. Guillain-Barré Syndrome, Greater Paris Area
  298. Vasopressin in sepsis: A world of complexity*
  299. Colloids in Septic Patients
  300. Mortality of patients with heatstroke admitted to intensive care units during the 2003 heat wave in France: A national multiple-center risk-factor study*
  301. Physiopathologie du choc septique
  302. Adrenal insufficiency in sepsis
  303. Emerging drugs for the treatment of sepsis
  304. The Highs and Lows of Intensive Insulin Therapy
  305. Relative Adrenal Failure in the ICU: An Identifiable Problem Requiring Treatment
  306. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome*
  307. Low-dose adrenocorticotropic hormone test is not ready for routine adrenal function testing in the intensive care unit*
  308. Glucocorticoids in the treatment of severe sepsis and septic shock
  309. Cardiovascular response to dopamine and early prediction of outcome in septic shock: A prospective multiple-center study*
  310. Etomidate and intensive care physicians
  311. ICU physicians should abandon the use of etomidate!
  312. Septic shock
  313. Corticoids Normalize Leukocyte Production of Macrophage Migration Inhibitory Factor in Septic Shock
  314. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update
  315. Managing toxic shock syndrome with antibiotics
  316. L’usage des corticoïdes en réanimation
  317. The effect of waiving consent on enrollment in a sepsis trial
  318. Corticosteroids for treating severe sepsis and septic shock
  319. The Neuropathology of Septic Shock
  320. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock
  321. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease
  322. Corticosteroids in Sepsis: From Bench to Bedside?
  323. Clinical Equipoise Remains for Issues of Adrenocorticotropic Hormone Administration, Cortisol Testing, and Therapeutic Use of Hydrocortisone
  324. Current Epidemiology of Septic Shock
  325. Time for a consensus definition of corticosteroid insufficiency in critically ill patients *
  326. Circulating vasopressin levels in septic shock
  327. Hormone replacement therapy for the critically ill *
  328. Physiological effects of decannulation in tracheostomized patients
  329. Cardiac and respiratory effects of continuous positive airway pressure and noninvasive ventilation in acute cardiac pulmonary edema
  330. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy
  331. Multifocal necrotizing leukoencephalopathy in septic shock
  332. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock
  333. Plasma exchange for Guillain-Barré syndrome
  334. Depletion of neurohypophyseal content of vasopressin in septic shock*
  335. The use of corticosteroids in severe sepsis and acute respiratory distress syndrome
  336. Prognostic factors in unintentional mild carbon monoxide poisoning
  337. Corticosteroids in Severe Sepsis
  338. Corticosteroids for septic shock
  339. Cardiac variability in critically ill adults: Influence of sepsis
  340. Clinical expert round table discussion (session 5) at the Margaux Conference on Critical Illness: Outcomes of clinical trials in sepsis: Lessons learned
  341. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders
  342. Compartmentalised inducible nitric-oxide synthase activity in septic shock
  343. A 3-Level Prognostic Classification in Septic Shock Based on Cortisol Levels and Cortisol Response to Corticotropin
  344. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders
  345. Inappropriate Sympathetic Activation at Onset of Septic Shock
  346. Short-term variability of blood pressure and heart rate in Guillain-Barré syndrome without respiratory failure
  347. Short-term variability of blood pressure and heart rate in Guillain-Barreá syndrome without respiratory failure
  348. Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size dependent phenomenon
  349. Steroid Replacement in Sepsis
  350. Myasthenic symptoms in patients with mitochondrial myopathies
  351. Kinetics of Elimination and Acute Consequences of Cerebral Air Embolism
  352. 964-10 Metoprolol Versus Disopyramide in the Management of Recurrent Neurocardiogenic Syncope
  353. 787-3 Efficacy and Safety of Early Administration of Intravenous Enalaprilat in Congestive Heart Failure Patients with Acute Pulmonary Edema
  354. Effects of mechanical ventilation with normobaric oxygen therapy on the rate of air removal from cerebral arteries
  355. Diaphragmatic paralysis preceding amyotrophic lateral sclerosis
  356. Transient left ventricular dyskinesia as a consequence of myocardial stunning
  357. The Place of Corticosteroids
  358. Faculty of 1000 evaluation for Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial.
  359. Faculty of 1000 evaluation for Surgical trauma-induced adrenal insufficiency is associated with postoperative inflammatory responses.
  360. Faculty of 1000 evaluation for Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.
  361. Faculty of 1000 evaluation for Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.
  362. Faculty of 1000 evaluation for Association between adrenal insufficiency and ventilator weaning.
  363. Faculty of 1000 evaluation for Effects of hydrocortisone on microcirculatory alterations in patients with septic shock.
  364. Faculty of 1000 evaluation for Intensive insulin therapy in the medical ICU.
  365. Faculty of 1000 evaluation for Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes.
  366. Faculty of 1000 evaluation for Duration of adrenal inhibition following a single dose of etomidate in critically ill patients.
  367. Faculty of 1000 evaluation for Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase.
  368. Faculty of 1000 evaluation for Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial.
  369. Faculty of 1000 evaluation for Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.
  370. Faculty of 1000 evaluation for Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia.
  371. The neuroendocrine response to critical illness